These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1994 related articles for article (PubMed ID: 31570100)

  • 1. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-release naltrexone opioid treatment at jail reentry (XOR).
    McDonald RD; Tofighi B; Laska E; Goldfeld K; Bonilla W; Flannery M; Santana-Correa N; Johnson CW; Leibowitz N; Rotrosen J; Gourevitch MN; Lee JD
    Contemp Clin Trials; 2016 Jul; 49():57-64. PubMed ID: 27178765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 4. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
    Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
    Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
    Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
    Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
    Farabee D; Condon T; Hallgren KA; McCrady B
    J Subst Abuse Treat; 2020 Oct; 117():108076. PubMed ID: 32811623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
    Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
    Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study.
    Cheng A; Badolato R; Segoshi A; McDonald R; Malone M; Vasudevan K; Badiei B; Sugarman A; Macdonald R; Mangat J; Giftos J; Lee JD; Tofighi B
    Addict Sci Clin Pract; 2022 Jan; 17(1):4. PubMed ID: 35093164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
    Shulman M; Choo TH; Scodes J; Pavlicova M; Wai J; Haenlein P; Tofighi B; Campbell ANC; Lee JD; Rotrosen J; Nunes EV
    J Subst Abuse Treat; 2021 May; 124():108292. PubMed ID: 33771287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.
    Gordon MS; Mitchell SG; Blue TR; Vocci FJ; Fishman MJ; Murphy SM; Couvillion K; Maher K; Ryan D; Wenzel K; Danner ML; Jarvis DK
    J Subst Abuse Treat; 2021 Sep; 128():108241. PubMed ID: 33339633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study.
    Brenna IH; Marciuch A; Birkeland B; Veseth M; Røstad B; Løberg EM; Solli KK; Tanum L; Weimand B
    J Subst Abuse Treat; 2022 May; 136():108667. PubMed ID: 34865937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
    Lier AJ; Seval N; Vander Wyk B; Di Paola A; Springer SA
    J Subst Abuse Treat; 2022 Nov; 142():108852. PubMed ID: 35988513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
    Andraka-Christou B; Capone MJ
    Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing outcomes of extended-release naltrexone in adolescents and young adults with opioid use disorder.
    Mitchell SG; Fletcher JB; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
    J Subst Use Addict Treat; 2024 Aug; 163():209162. PubMed ID: 37730015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis.
    Hoffman KA; Baker R; Fanucchi LC; Lum PJ; Kunkel LE; Ponce Terashima J; McCarty D; Jacobs P; Korthuis PT
    Addict Sci Clin Pract; 2021 Nov; 16(1):67. PubMed ID: 34758887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare utilization and costs associated with treatment for opioid dependence.
    Shah A; Duncan M; Atreja N; Tai KS; Gore M
    J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
    Jackson H; Mandell K; Johnson K; Chatterjee D; Vanness DJ
    Subst Abus; 2015; 36(2):226-31. PubMed ID: 25775099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
    Jalali A; Jeng PJ; Polsky D; Poole S; Ku YC; Woody GE; Murphy SM
    J Subst Abuse Treat; 2022 Oct; 141():108835. PubMed ID: 35933942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 100.